Clinical and non-clinical use of MDMA.
Tidsskr Nor Laegeforen June 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al.
Clinical and non-clinical use of MDMA.
Ole A. Andreassen
7 papers in the library · 35 citations · publishing 2018-2026
Papers
The non-classic psychedelic muscimol suppresses inflammatory signaling and promotes neuroplasticity in schizophrenia-derived human cortical spheroids and astroglia
bioRxiv (Cold Spring Harbor Laboratory) April 12, 2026 Ibrahim A. Akkouh, Jordi Requena Osete, N. W. Steen et al.
ABSTRACT Schizophrenia (SCZ) is increasingly linked to neuroimmune dysregulation and impaired synaptic plasticity, yet the cellular mechanisms connecting inflammatory signaling to neural dysfunction remain poorly understood. Using human induced pluripotent stem cell (iPSC)-derived cortical spheroids (hCS) and astrocytes from patients with SCZ and matched controls, we investigated the effects of...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study - CORRIGENDUM.
Br J Psychiatry February 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al.
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial
Journal of Psychiatric Research November 27, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Joanna Róg et al. 3 citations
BACKGROUND: Major depressive disorder (MDD) is a leading cause of global disability, and current treatments often fail to provide sustained effectiveness. MDMA-assisted therapy (MDMA-AT) is a promising treatment for MDD. However, the long-term effects are not known. OBJECTIVES: To examine the long-term effects of MDMA-AT for MDD. METHODS: Twelve participants with MDD and an ongoing moderate to...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study.
The British journal of psychiatry : the journal of mental science July 11, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al. 6 citations
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic stress disorder, but has not been investigated for a primary diagnosis of major depressive disorder (MDD). We aimed to explore the proof of principle and safety as a first study with MDMA-AT for MDD, and to provide preliminary efficacy data. Twelve...
Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”
Frontiers in Psychiatry October 26, 2022 Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al. 11 citations
Background Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and there is a significant need for more effective treatment options. Here we present the protocol for an investigator-initiated and publicly funded trial of MDMA-assisted therapy (MDMA-AT) for MDD. This single-site, open-label study investigates the...
Psykedeliske stoffer i behandling av angst, depresjon og avhengighet
Tidsskrift for Den norske legeforening 2018 Tor-Morten Kvam, Lowan H. Stewart, Ole A. Andreassen 15 citations
Psykedeliske stoffer i behandling av flere psykiske lidelser har vist lovende resultater, men studiene er små og har metodologiske utfordringer. Det er behov for systematiske kliniske studier for å skaffe solid dokumentasjon for effekt og etablere rutiner for overvåkning av mulige bivirkninger.